Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Reference Study ID Number: CO43805 https://forpatients.roche.com/ 888-662-6728
global-roche-genentech-trials@gene.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Back

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Recruiting

Open to: ALL

Age: 18.0 - N/A

Glasgow Nottingham London Oxford

Medical Conditions

Lymphoma
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 and/or CC-99282) in participants with B-cell NHL.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Oct 2022 Mar 2027

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Participants will receive SC mosunetuzumab for 12 cycles (cycle length = 21 days or 28 days for Cycle 1 and 28 days for Cycles 2-12)

Intervention Arm Group : Arm 1;

Intervention Type : DRUG
Intervention Description : Participants will receive IV glofitamab for 12 cycles (cycle length = 21 days)

Intervention Arm Group : Arm 2;

Intervention Type : DRUG
Intervention Description : Arm 1: Participants will receive oral CC-220 from Day 1-21 of Cycle 2-12 (cycle length = 28 days for Cycles 2-12)

Intervention Arm Group : Arm 1;

Intervention Type : DRUG
Intervention Description : Arm 1: Participants will receive oral golcadomide from Day 1-14 starting in either Cycle 1 or Cycle 2 through Cycle 12 (cycle length = 28 days for cycles when golcadomide is to be administered) Arm 2: Participants will receive oral golcadomide from Day 1-10 starting in either Cycle 1, Cycle 2 or Cycle 3 through Cycle 12 (cycle length = 21 days)

Intervention Arm Group : Arm 1;Arm 2;

Intervention Type : DRUG
Intervention Description : Participants in Arm 2 will receive pre-treatment with IV obinutuzumab on Cycle 1 Day 1 (cycle length = 21 days)

Intervention Arm Group : Arm 2;

Intervention Type : DRUG
Intervention Description : Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS)

Intervention Arm Group : Arm 1;Arm 2;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • NHS Greater Glasgow and Clyde
    Glasgow
    G12 0YN
  • Nottingham University Hospitals City Campus
    Nottingham
    NG5 1PB
  • University College London Hospitals
    London
    W1T 7HA
  • Oxford University Hospitals NHS Trust;Churchill Hospital
    Oxford
    OX3 7LE

Reference Study ID Number: CO43805 https://forpatients.roche.com/ 888-662-6728
global-roche-genentech-trials@gene.com



The study is sponsored by Hoffmann-La Roche



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT05169515
Last updated 02 May 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top